Oxford Biomedica To Start Trading On London's AIM

16 December 1996

- Oxford Biomedica expected to start trading on London's Alternative Investment Market on December Friday 13, after the Marketletter went to press, following delays caused by two underwriters who withdrew from the offer. Instead of the L8 million ($13.2 milllion) expected from the placing and open offer for 10% of the company, only L5 million was raised after the underwriters pulled out (Marketletters passim). The company is "reserving its legal postion" on the matter, reports the Financial Times.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight